bit.bio
bit.bio is an award-winning human synthetic biology company whose mission is to code cells for novel cures. They have developed an end-to-end platform for the creation of any human cell type. With their cutting-edge and patent-protected opti-ox™ precision cell programing technology, bit.bio can deterministically program human induced pluripotent stem cells (iPSCs) into a chosen cell identity with unprecedented biological consistency at an industrial scale and approximately 10 times faster than conventional methods. Their platform has the potential to unlock a new generation of medicines.
Latest Content
Webinar
Master MEA Experiments With iPSC-Derived Neurons
On-Demand
This webinar provides expert guidance from leading specialists who will share proven methodologies, troubleshooting techniques and real-world data analysis approaches to help you generate robust MEA results with confidence.
How To Guide
Expert Tips for Reproducible Neuronal Research
This guide provides field-tested strategies and expert insights to help achieve consistent, reproducible MEA results with human iPSC-derived neurons.
Industry Insight
Simplifying Cell Visualization in Complex Model Systems
bit.bio’s GFP ioMicroglia enables real-time tracking of microglia in complex co-cultures and in vivo, streamlining neurodegeneration research and drug discovery.
Product News
bit.bio Launches ioTracker Cells Range at SLAS 2025
bit.bio, announces the launch of its ioTracker Cells range, starting with GFP ioMicroglia, a progressive tool designed to accelerate complex neurodegenerative disease research and drug discovery.
Online Event
Innovations in Disease Modeling 2025
On-Demand
This event will cover innovations in advanced in vitro and in vivo disease modeling and how these advancements are accelerating drug discovery, personalized medicine and our understanding of complex disease mechanisms.
Webinar
Human iPSC-Based Models of Glial Cells for Studying Neurodegenerative Disease
On-Demand
The increasing implication of glial cells in neurodegenerative diseases makes them an appealing addition to iPSC-based model systems for investigating disease mechanisms.
Industry Insight
Exploring Human iPSC-Derived Astrocytes for Advancing CNS Research
In this interview, Dr. Mitzy Rios de Anda sheds light on the potential of human iPSC-derived astrocytes, discussing how these cells are reshaping our understanding of the brain, neurological diseases and therapeutic development.
Video
Leveraging Human iPSC-Derived Astrocytes for Neurological Research and Therapy
In this episode we speak with bit.bio about astrocytes and how bit.bio's innovative technology is transforming research in this area.
Webinar
Powering a New Generation of Physiologically-Relevant CRISPR Screens
On-Demand
CRISPR-Cas9 gene editing is an essential functional genomics tool, facilitating the cataloging of genomic variations linked to human diseases for the discovery and validation of novel drug targets.
Product
Advertisement
ioAstrocytes - Human iPSC-Derived Astrocytes
ioAstrocytes offer a solution to researchers who are searching for easy-to-use, highly characterised human cells that are designed for co-culture and effectively recapitulate astrocyte functions within CNS models in vitro
Advertisement
